Castrate Resistant Prostate Cancer / Androgen Insensitive, Hormone Refractory Disease/ Chemotherapy
Posted on: 11/01/2009
Provenge: Benefit Increased When Used at Lower Baseline PSA Values (July - August 2013)
ZYTIGA (Abiraterone (July-August 2013)
MDV3100 - Now FDA Approved (November-December 2012)
ABIRATERONE: A Brief Update (March-April 2012)
MDV3100 - Phase III "AFFIRM" Trial Demonstrates Survival Benefit (March-April 2012)
Abiraterone: Encouraging Phase III Trial Results Move Drug Towards FDA Approval (Nov-Dec 2010)
A Heads Up (About Prostate Cancer Vaccine) (March-April 2010)
MDV-3100: A Third Generation Anti-Androgen: Available on Protocol (May-June 2010)
Custirsen: An Antisense Therapy (July-Aug 2009)
Increased Androgens After Castration (July-Aug 2009)
Provenge: Dendreon's Prostate Cancer Vaccine (Nov-Dec 2009)
MDV3100 - A Promising Drug in Early Trials for Castrate Resistant Prostate Cancer (May-June 2009)
Intermittent Chemotherapy - When Is Enough Enough? (May 2008)
Chemotherapy - Updated Survival Data from TAX 327 Study: Docetaxel Plus Prednisone Versus Mitoxanthrone Plus Prednisone for Advanced Prostate Cancer. (JCO January 10, 2008) (March 2008)
Latest Report Of 'Accent': Docetaxel And Calcitriol (October 2006)
Intermittent Chemotherapy in Metastatic Prostate Cancer (June 2006)
PSADT Predicts Survival In Hormone Refractory Prostate Cancer (August 2005)
Chemotherapy For Hormone Refractory Prostate Cancer: The Context and the New Content (April 2005)
Duration Of Survival Of Patients Who Developed Hormone Refractory Prostate Cancer (August 2004)
Intermittent Chemotherapy for Chemotherapy Responders - An Early Trial (August 2003)
Neoadjuvant chemotherapy for "high risk" prostate cancer - ready for prime time? (June 2003)
MSKCC nomogram predicts survival for patients who fail androgen ablation therapy (November 2002)
In This Section
